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The oncogenic phosphatase of regenerating liver 2 (PRL-2)
has been shown to regulate intracellular magnesium levels by
forming a complex through an extended amino acid loop
present in the Bateman module of the CNNM3 magnesium
transporter. Here we identified highly conserved residues
located on this amino acid loop critical for the binding with
PRL-2. A single point mutation (D426A) of one of those crit-
ical amino acids was found to completely disrupt PRL-2hu-
man Cyclin M 3 (CNNM3) complex formation. Whole-cell
voltage clamping revealed that expression of CNNM3 influ-
enced the surface current, whereas overexpression of the
binding mutant had no effect, indicating that the binding of
PRL-2 to CNNM3 is important for the activity of the complex.
Interestingly, overexpression of the CNNM3 D426A-binding
mutant in cancer cells decreased their ability to proliferate
under magnesium-deprived situations and under anchorage-
independent growth conditions, demonstrating a PRL-
2CNNM3 complex-dependent oncogenic advantage in a
more stringent environment. We further confirmed the
importance of this complex in vivo using an orthotopic xeno-
graft breast cancer model. Finally, because molecular model-
ing showed that the Asp-426 side chain in CNNM3 buries into
the catalytic cavity of PRL-2, we showed that a PRL inhibitor
could abrogate complex formation, resulting in a decrease in
proliferation of human breast cancer cells. In summary, we
provide evidence that this fundamental regulatory aspect of
PRL-2 in cancer cells could potentially lead to broadly appli-
cable and innovative therapeutic avenues.
Protein tyrosine phosphatases (PTPs)2 constitute a large
family of enzymes that can exert both positive and negative
effects on signaling pathways (1). The phosphatases of regener-
ating liver 1, 2, and 3 (PRL1–3, also known as PTP4A1–3) are
members of the PTP family that are highly expressed in the
majority of human solid tumors as well as in hematological
cancers (2–4). They are weakly active in in vitro enzymatic
assays using synthetic substrates, and some physiological sub-
strates have been proposed but remain to be confirmed (5–8).
Despite recent publications in the cancer field, the normal
physiological functions of PRLs are poorly understood. In our
recent work, we uncovered a new paradigm whereby PRLs reg-
ulate magnesium transport by forming a complex with the
CNNM magnesium transporters to promote breast cancer
development (5). Such an association was later reported by
Funato et al. (9), thus establishing a novel role for PRLs in the
regulation of intracellular magnesium levels.
Like protein phosphorylation, the intracellular magnesium
balance is altered in transformed cells and has been linked to
modifications of several hallmarks of cancer (10). Importantly,
high intracellular levels of this metal cation seem to confer a
metabolic advantage to cells and to promote acquisition of a
transformed phenotype (11–13). In recent years, the existence
of novel mammalian genes encoding proteins directly involved
in the transport of magnesium through cell membranes has
been uncovered (14). Among those is the human Cyclin M
(CNNM) gene family comprising four homologs (CNNM1–4)
that are differentially expressed in human tissues and are pres-
ent throughout evolution (15, 16). Genome-wide studies
showed that CNNM2-, CNNM3-, and CNNM4-specific single
nucleotide polymorphismswere associated with serummagne-
sium concentrations, supporting the role of these proteins in
human magnesium homeostasis under physiological condi-
tions (17).
Secondary structure prediction for the CNNMs suggests the
presence of three transmembrane domains located at the
N-terminal region and a C terminus containing a cystathionine
 synthase (CBS) pair domain (Bateman module) essential for
the binding to PRLs via a unique extended amino acid loop
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absent in other CBS-containing proteins (5, 16). Interestingly, a
mutation in the Bateman module of CNNM2 was reported to
cause a dominant form of blood hypomagnesemia (18), con-
firming the importance of this CNNM region in the regulation
of magnesium homeostasis. Currently, seven families with
CNNM2mutations suffering fromhypomagnesemia have been
described (18, 19).
Here we identified a highly conserved residue located in the
extended amino acid loop of the second CBS domain of all
CNNMs that is critical for the PRL-2CNNM3 oncogenic func-
tion. Furthermore, blocking the formation of this complex
using a small molecule inhibitor showed an antiproliferative
effect on human breast cancer cells, indicating a potential novel
therapeutic avenue to treat cancer patients.
Experimental Procedures
Conservation of the CNNMs BatemanModule andModeling
of the CNNM3PRL2 Complex—ConSurf (20) was used to cal-
culate the sequence conservation score of the CNNM2 Bate-
man module (PDB code 4IY0) and its homologues. The struc-
ture figure was rendered using the UCSF Chimera 1.10.2
package (21). Because of the lack of coordinates for CNNM3
and PRL-2 in the databases, the first step for modeling their
interaction consisted of constructing suitable three-dimen-
sional templates of the two interacting proteins from their clos-
est homologs (CNNM2, PDB code 4IY4; PRL1, PDB code
1XM2). After substituting the variant residues manually with
COOT (22), an optimization of the overall geometry was car-
ried out with PHENIX (23). The protein-protein docking pre-
diction was done with ZDOCK (24). ZDOCK is a fast Fourier
transform-based protein-docking program that searches all
possible bindingmodes in the translational and rotational space
between two structural models and evaluates each pose using
an energy-based scoring function.
Plasmid Construction, Transfection, and Pulldown
Experiments—Cloning of human PRL-2 and CNNM3 into
pDEST15, pDEST17, pLenti6-v5, pcDNA3.1 FLAG, pcDNA3.0
His-FLAG-DEST, and pDEST27 (Open Biosystems, Thermo
Scientific) were described previously (5). Point mutations were
introduced by site-directedmutagenesis using theQuikChange
site-directed mutagenesis kit (Stratagene, Agilent Technolo-
gies, Santa Clara, CA). The luciferase reporter gene was also
cloned in pMSCV-Puro internal ribosomal entry siteGFP, a gift
from Scott Lowe (Memorial Sloan Kettering Cancer Center,
New York, NY; Addgene plasmid 18751) to produce a pMSCV-
Puro internal ribosomal entry site GFP luciferase plasmid.
HeLa cells were transfected with various plasmids, followed by
either GST pulldown or FLAG immunoprecipitation as
described previously (5). HeLa cells were used only as a mam-
malian expression tool to produce the recombinant protein
required for pulldown experimentation.
Co-infection in DB-7 and CNNM3 Stable Line Production—
DB-7 cells were stably co-infected using the lentiviral vector
pLenti6-v5 (Invitrogen) containing the human CNNM3 gene
and the retroviral MSCV-Puro internal ribosomal entry site
GFP luciferase construct. First, HEK293T/17 cells were trans-
fected with the appropriate lentiviral or retrovirus constructs
using Lipofectamine 2000 (Invitrogen). Cultured supernatants
were collected 36–48 h after transfection and filtered. DB-7
cells were co-infected with the filtered viral supernatants in a
1:1 ratio in the presence of 4 g/ml Polybrene for 48 h, after
which themediumwas changed. Following infection, cells were
selected with 5 g/ml blasticidin and 2 g/ml puromycin for 2
weeks, and the resistant population was used for cellular assays.
Electrophysiology—All currents were recorded using an Axo-
patch 200B amplifier (Axon Instruments, Sunnyvale, CA) cou-
pled to a CV 203BU headstage in the whole-cell patch clamp
configuration. To ensure adequate voltage control, a minimum
of 80% series resistance compensation was required along with
an access resistance of 10 megohms. Command pulses were
generated by a Digidata 1440A controlled by pClamp 10.4 soft-
ware (Axon Instruments). HEK293 cells are extensively used as
an expression tool to study isolated receptor channels and
transporters activities (25). The HEK293 cells were clamped at
a holding potential of 0 mV, fromwhich 2-s steps were made in
increments of 25 mV over the range of 150 to 25 mV, fol-
lowed by a return to 0 mV. Data were acquired at 20 kHz and
low pass-filtered at 2 kHz. Peak current amplitudes were quan-
tified using Clampfit 10.4. All current values were normalized
to cellular capacitance (picofarads). Borosilicate glass pipettes
(Warner Instruments, Hamden, CT) were prepared with a
microprocessor-controlled multistage puller (P97, Sutter
Instruments, Novato, CA) to produce a tip resistance of 2–4
megohms when filled with 135 mM KCl, 5 mM EGTA, and 10
mMHEPES (pH7.2) withKOH (275mosM). Cells were plated in
the perfusion chamber of an inverted microscope (Zeiss Axio-
vert S100TV) and perfused using a gravity-based flow system (2
ml/min) containing Tyrode solution (135 mMNaCl, 5 mM KCl,
2mMMgCl, 10mMHEPES (pH7.4withNaOH, 275mosM)). All
experiments were performed at room temperature.
Cellular Proliferation—Cell were seeded in a 96-well plate
with 5000 cells/well, and quantification was performed at 12,
24, 48, and 72 h using the CyQuant cell proliferation assay kit
(Invitrogen/Life Technologies). For magnesium modulation
experiments, cells were allowed to adhere in complete medium
for 12 h. After one PBS wash, magnesium-free DMEM (Wisent
Inc.) with dialyzed FBS was used to vary the concentrations of
magnesium by the addition ofMgCl2. The relative fluorescence
was detected at 485-nm excitation/527-nm emission using a
96-well plate reader (Varioskan Fluostar, Thermo Scientific)
and relative fluorescence values were then plotted at each time
point. The proliferation of human MCF-7 cells was monitored
using a real-time cell analyzer instrument, the xCELLigence
system (Roche Applied Science). The cells were seeded in
E-plate (Roche Applied Science) with 5000 cells/well. After
overnight incubation, various concentrations of inhibitor were
added to each well, and the cell index values were monitored at
5-min intervals for the first 6 h and then every 15 min for 96 h.
Incubation with dimethyl sulfoxide was also performed as a
vehicle control by adding an equivolume of dimethyl sulfoxide
compared with the highest inhibitor volume treatment. Three
replicates of each concentration of the inhibitor were used for
this experiment. The data from the real-time cell analyzer
software were exported and analyzed with Prism software
(GraphPad, version 6).
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Cell Surface Biotinylation—HEK293 cells were transfected
with wild-type and mutant CNNM3/PRL-2 constructs for 48 h
using Lipofectamine (Invitrogen) in 1:2 DNA:Lipofectamine
ratio. Subsequently, cell surface proteins were biotinylated as
described previously (19). Briefly, cell surface proteins were
biotinylated for 30min at 4 °C in 0.5mg/ml Sulfo-NHS-LC-LC-
Biotin (Pierce). Cells were washed and lysed in lysis buffer (150
mM NaCl, 5 mM EGTA, Triton 1% (v/v), 1 g/ml pepstatin, 1
mM PMSF, 5 g/ml leupeptin, 5 g/ml aproptin, and 50 mM
Tris/HCl (pH 7.5)). 10% of the sample was taken as input con-
trol, and the rest of the protein lysateswere incubated overnight
with NeutrAvidin-agarose beads (Pierce) at 4 °C.
Colony Formation in Soft Agar—Anchorage-independent
growth in soft agar was measured by colony formation assay as
described previously (3). The size of each colony was measured
using Ilastik image processing tool version 1.1.8 (26). Colonies
sizes were then normalized with their respective total colony
number and divided into small (50 to 500 pixels), medium
(500 to1000 pixels) and large (1000 pixels) categories.
Xenograft Assay and inVivo Bioluminescence Imaging—Mice
(NU/J, 6 weeks old) were injected in the no. 4mammary fat pad
with 1  106 DB-7 mammary cancer cells stably expressing
empty vector, CNNM3-V5, or CNNM3 D426A-V5 as de-
scribed previously (5). In vivo imaging of the injectedDB-7 cells
also expressing the luciferase reporter gene was performed
using a Xenogen IVIS-100 imaging system (Xenogen Inc.). The
mice were placed into the imaging chamber of the system 10
min after D-luciferin intraperitoneal injection (150 mg/kg)
under anesthesia by isoflurane gas (2%, inhalation). Analysis of
the emitted bioluminescence was performed using Live Image
Pro. 2.5 software (Caliper Life Science), and fluorescence inten-
sities were expressed as total flux (photons per square centime-
ter per steradian) were measured by drawing a rectangular
region of interest over the entire injection area.
In Vitro Pull-down Assay with Thienopyridone—The 16-kDa
Bateman module of human CNNM3 (amino acids 302–452)
and the 19-kDa PRL-2 construct were expressed in Escherichia
coli BL21 and purified as described previously (5). Glutathione-
Sepharose beads were washed with precooled binding buffer
(150mMNaCl, 20mMTris, 1%Triton-X, 1 complete protease
inhibitor mixture (Roche), and 5 mM 2-mercaptoethanol), and
20 ng of either purified GST or GST-CBS protein was added to
the beads and incubated at 4 °C for 1 h, followed by three
washes with the binding buffer. In parallel, an equimolar
amount ofHis-PRL-2 protein (10 ng)was distributed in a new
set of tubes to which various concentrations of thienopyridone
(inhibitor) were added. The His-PRL-2/inhibitor solution was
incubated at 4 °C for 20 min and then added to the GST- or
GST-CBS-bound beads. This final mixture was incubated at
4 °C for 1 h, and then the beads were washed three times with
binding buffer. Bead-bound proteins were boiled in SDS load-
ing buffer before Western blotting analysis.
Results
Identification of Critical Residues in CNNM3 Is Essential for
the Interaction with PRL-2—We demonstrated previously that
a complete deletion of the amino acid loop of the second CBS
domain of the Bateman module or a mutation disturbing the
full structure of the Bateman module of CNNM3 was able to
abolish its interaction with PRL-2 (5). Because the degree to
which an amino acid position is conserved during evolution
depends strongly on its functional importance, we used the
publicly available crystal structure of the CNNM2 Bateman
module to determine its conservation among 150 homologous
eukaryotic sequences using ConSurf (20) (supplemental Fig. 1).
This approach yielded a nearly perfect conservation of the
amino acid loop in higher eukaryotes. Remarkably, we identi-
fied two amino acids in the loop of CNMM3 that were perfectly
conserved in the entire analysis: aspartic acid 426 and proline
427 (Fig. 1A). Thus, wewanted to further characterize the bind-
ing affinities of all residues present on the extended loop by
mutating each of the amino acids from 424 to 429 by alanine to
identify the critical residue(s) involved in the complex forma-
tion. We examined their binding abilities by co-transfecting
GST-PRL-2 and FLAG-2xCBS (Bateman module) mutants of
CNNM3 in HeLa cells, followed by FLAG immunoprecipita-
tion. Interaction was completely lost when the 2xCBS mutants
D426A, P427A and Y429A were independently expressed (Fig.
1B). Interestingly, the 2xCBS T436Imutation corresponding to
the T568I mutation in CNNM2, shown to cause hypomag-
nesemia in human (18), also reduced PRL-2 binding. The
importance of the two most conserved amino acids (Asp-426
and Pro-427, identified in Fig. 1A) was further confirmed by
co-transfecting GST-PRL-2 and the full-length CNNM3
mutants in HeLa cells, followed by GST pulldown (Fig. 1C).
From those findings, we selected the Asp-426 mutant to con-
tinue our investigation, given that charged residues are known
to promote high-affinity protein binding (27, 28) and because of
the very high conservation of Asp-426 in other eukaryotic
CNNMs. Because we demonstrated previously that disturbing
the full structure of the Bateman module using the CNNM3
G433Dmutant was able to alter the interaction with PRL-2 (5),
we compared its effect with that of the D426A mutant and
showed that they both equally decrease the binding with PRL-2
(Fig. 1D). Importantly, this aspartic acid was furthermutated to
vary both the length and the charge of the residue to determine
the necessity of aspartic acid at this position in the loop to
mediate the interaction with PRL-2 (Fig. 1E).
We recently found that mutations of essential catalytic resi-
dues in PRL-2, like D69A or C101S, also cause loss of interac-
tion with CNNM3, suggesting that residues within the catalytic
cavity are critical for complex formation (5). Prompted by these
findings and ourmutagenesis of the Batemanmodule described
above, we scrutinized the interactions underlying the human
PRL-2CNNM3 assembly by molecular modeling approaches.
Using the ZDOCK protein-protein docking prediction pro-
gram (24), we established the top 10 possible docking orienta-
tions of the complexes that could be grouped in three different
types of arrangement (supplemental Fig. 2). The highest scored
was the one that proposes a direct interaction between the
extended loop ofCNNM3and the catalytic cavity of PRL-2 (Fig.
1F). According to this model, the two proteins associate
through electrostatic interactions participated in by three
acidic residues, Glu-422, Glu-424, and Asp-426, of the
extended loop (Fig. 1, B and F). Interestingly, the side chain of
Asp-426 buries into the catalytic cavity of PRL-2 and occupies a
CNNM3 Is Required for PRL-2 Oncogenic Activities
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nearby position of the phosphatase potential substrates. Two
alternating glycines, located at positions 423 and 425, allow the
acidic residues to face the surface of PRL-2.On the contrary, the
N- and C-terminal residues of the loop (Asn-420 and Phe-428)
point toward the outside of the catalytic cavity, suggesting a
secondary role in the interaction. Taken together, our findings
establish the importance and specificity of aspartic acid 426 of
CNNM3 for binding with PRL-2 to form a stable protein
complex.
Functional Characterization of the CNNM3WT and D426A
Mutant—CNNM2 has been shown to reside at the plasma
membrane, and membrane topology studies showed that
CNNM2has an extracellular N terminus plus an intracellular C
terminus that contains the Bateman module (16). Accordingly,
to determine themembrane expression of the CNNM3mutant
that has lost its ability to interact with PRL-2, cell surface bioti-
nylation assays of the CNNM3WT-v5 and CNNM3D426A-v5
mutants overexpressed in HEK293 cells in the presence of
FLAG-PRL-2 were performed (Fig. 2A). The presence at the
plasma membrane of the CNNM3 WT and mutant correlates
with their levels of ectopic expression and was not affected by
the presence of PRL-2. This suggested that neither the muta-
tions nor PRL-2 affect CNNM3 membrane stability and levels
at the cell surface.
To examine the influence of CNNM3 on magnesium trans-
port, we investigated the functional characteristics of CNNM3
by transfecting CNNM3WT or CNNM3 D426A into HEK293
cells and electrophysiologically recorded these cells using
whole-cell patch clamping. Fig. 2B shows that CNNM3 WT
tends to shift the whole-cell macroscopic current-voltage rela-
tionship in the inward direction relative to that of non-trans-
fected cells. The current-voltage relationship of CNNM3
D426A fell between those of CNNM3WT and non-transfected
cells. Importantly, when current magnitude was measured at
the epithelial physiological resting potential of 50 mV (Fig.
2C), there was a significantly larger inward current in cells
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FIGURE 1.Aspartate 426 of CNNM3 is critical for complex formationwith PRL-2.A, the structure of the Batemanmodule of CNNM2 is colored based on the
residue conservation, ranging from cyan (lowest) tomagenta (highest). The twomost highly conserved residues, Asp-426andPro-427, are indicatedon theCBS
loop. The sequence alignments of the amino acid loop from the representative Batemanmodule of various CNNMhomologues are shown in the bottompanel.
The conservation score and the ConSurf histogram indicate the rate of conservation of a particular residue within 150 homologous sequences. B, HeLa cells
were transiently co-transfected with GST-PRL-2 and either the tandem CBS domain of CNNM3 or various mutants. FLAG immunoprecipitation (IP) was
performedoncell extracts, followedbyWesternblottinganalysiswitheitherGSTor FLAGantibodies. EV, empty vector;TCL, total cell lysate.C–E, HeLa cellswere
transiently co-transfected with GST-PRL-2 and either the full-length CNNM3 or various mutants. GST pulldown was performed on cell extracts, followed by
Western blotting analysis with either v5 or GST antibodies. F, the figure, extracted from the in silico model obtained with ZDOCK software, represents the
interaction zonebetweenCNNM3andPRL-2. The surface of PRL-2 is shown in surface representation and colored according to electrostatic potential (positive,
blue; negative, red). The interaction of the extended loop linking the last two  strands of the CBS2 motif of CNNM3 (yellow ribbons) with the residues of
the catalytic site of PRL-2 or its surroundings occurs mainly through electrostatic forces. The tight turns of the loop are favored by the alternate glycines and
proline preceding or following its acidic residues.
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transfected with CNNM3WT compared with non-transfected
cells. In contrast, the currents recorded from cells transfected
withCNNM3D426Awere not significantly different fromnon-
transfected cells, suggesting that the binding of PRL-2 to
CNNM3 is important for the function of the complex.
Disruption of the PRL-2/CNNM3 Complex Decreases Cell
Proliferation and Tumors—The regulation of intracellular
magnesium levels by PRLs in cancer has been proposed previ-
ously to be mediated by its interaction with the CNNMs mag-
nesium transporter family (5, 9), but the structural basis of this
interaction is still obscure. To assess the oncogenic potential of
the PRL-2CNNM3 complex, we first investigated the role of
the CNNM3 D426A mutant, which has lost its ability to inter-
act with PRL-2, in cellular proliferation by establishing cell lines
stably expressing an empty control vector (pLenti6/v5),
CNNM3 WT, or CNNM3 D426A in mouse DB-7 tumor-de-
rived cell lines known to form tumors when injected into
murine mammary fat pads (3, 29). Although there was no dif-
ference in cellular proliferation between empty vector-,
CNNM3 WT-, and D426A-expressing cells using standard
medium (Fig. 3A, left panel), we hypothesized that the loss of
interactionwith PRL-2might have a disadvantageous effect in a
more stringent environment. Because the CNNM3/PRL-2
interaction is promoted by the presence of low extracellular
magnesium levels (5), we tested the ability of the stable cell lines
to proliferate in magnesium-deprived medium (Fig. 3A, center
and right panels). Interestingly, we found that only the overex-
pression of CNNM3 D426A impaired the ability of the cell to
grow in magnesium-depleted medium (Fig. 3A, right panel),
suggesting a critical role for the PRL-2CNNM3 complex in
magnesium-dependent proliferation.
To further evaluate the effect of this interaction on the
tumorigenic capacity of the cells, we subjected the DB-7 stable
cell line to anchorage-independent growth, which is a hallmark
of a transformed phenotype (30, 31). We observed that overex-
pression of CNNM3 WT favored colony formation (Fig. 3B)
and that it had an increased proportion of large colonies (Fig.
3C) compared with both control and D426A mutation. Thus,
the data support an essential role for PRL-2 in CNNM3-depen-
dent cell proliferation in a stringent environment.
To translate the importance of our findings to an in vivo
context, we used an orthotopic xenograft model that closely
mimics tumor microenvironments, including magnesium
availability. Thus, to assess the oncogenic capability of the
CNNM3 D426A mutant that lost its ability to interact with
PRL-2, we generated stable mouse mammary tumor DB-7 cells
(3) co-overexpressing CNNM3 WT-v5 or CNNM3 D426A-v5
(Fig. 4A) and luciferase, which were injected in the mammary
fat pads of athymic nude female mice. The luciferase activity of
those cell lines was measured prior to injection and was similar
for all conditions (data not shown). A bioluminescence imaging
system also confirmed a similar luciferase signal of the DB-7
stable cell lines present at the injection site. Early after tumor
injection, we observed lower luciferase activity in cells overex-
pressing CNNM3 D426A, which was consistent on days 7 and
10 (Fig. 4, B and E). Remarkably, cells overexpressing the
CNNM3 D426A mutant presented reduced tumor size com-
pared with an exponential growth for both empty control and
wild-type protein (Fig. 4C). Moreover, the tumors were dis-
sected at the experimental end point, andwe similarly observed
that cells overexpressing the mutant had a lower tumor burden
(Fig. 4D). Together, these results demonstrate that the ability of
CNNM3 to interact with PRL-2 is essential for tumor progres-
sion and that blocking PRL-2CNNM3 complex formation in
vivo causes a growth disadvantage for the tumor cells.
The PRLs Inhibitor Thienopyridone Blocks the Interaction
between PRL-2 and CNNM3 to Reduce Cancer Cell
Proliferation—Our CNNM3PRL-2 modeling indicates that
the side chain of the Asp-426 residue buries into the catalytic
cavity of PRL-2 and occupies a position near the phosphatase
potential substrate site (Fig. 1F). Thus, we speculated that a
competitive inhibitor of PRL-2 could abrogate the interaction
withCNNM3and, according to our results described above, the
oncogenic activity of the complex. Thienopyridone is a known
C
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FIGURE 2. Functional characterization of CNNM3 WT and the D426A
mutant. A, HEK293 cells were transiently co-transfected with CNNM3-v5 and
FLAG-PRL-2 constructs. The cell surface was biotinylated, and the cell extract
was subjected to a streptavidin-agarose pulldown and immunoblot analysis.
TCL, total cell lysate. B, current-voltage relationship was obtained from volt-
age clamp protocols that involved a holding potential of 0mV fromwhich 2 s
steps were made in increments of 25 mV over the range of150 mV to25
mV, followedby a return to 0mV (n 5, black; CNNM3-WT-transfected, n 6,
gray, and CNNM3-D426A-transfected HEK293 cells, n 8, dashed). pF, pico-
farad. C, quantitative measurement of current magnitude from the three
groups represented in B at the physiological epithelial voltage of50mV. All
data are expressed as mean S.E. *, p 0.0322 by one-way ANOVA.
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specific inhibitor of PRLs that was shown previously to impair
their enzymatic activities and decrease both the proliferation
and migration abilities of cells overexpressing PRLs (32, 33).
We first investigated the effect of this small inhibitor on the
binding of recombinant PRL-2 and the Bateman module of
CNNM3 in vitro by performing a pulldown experiment in the
presence of various concentrations of inhibitor. In this assay,
thienopyridone was able to disrupt the binding between PRL-2
and CNNM3 (Fig. 5A). Because MCF-7 human breast cancer
cells expressed both PRL-2 and CNNM3 (5), we tested their
proliferation rate with various concentrations of thienopyri-
done using the xCELLigence system (Fig. 5B) and showed that
this small molecule inhibitor was able to decrease cell prolifer-
ation (Fig. 5C). These results strongly suggest that the mecha-
nism by which this inhibitor impairs cellular growth is through
inhibition of the PRL-2 interaction with CNNM3.
Discussion
In this study, we identified a highly conserved aspartic acid
located on the extended loop of the Bateman module of
CNNM3 critical for the binding with PRL-2. This observations
is consistent with the fact that most protein-protein interac-
tions are mediated by non-helical, non-strand peptide loops
(34). Using a CNNM3mutant (D426A) that has lost its capacity
to interact with PRL-2 or a smallmolecule inhibitor of the com-
plex formation between these two proteins, we showed that this
interaction is important for breast cancer cell proliferation and
tumor growth.
CNNM3 WT CNNM3 D426AEmptyD
10x10x 10x
C
B
MgCl2MgCl2A
FIGURE 3.Overexpressionof CNNM3D426A inDB-7mammary cancer cells decreases proliferation.A, proliferation assays of DB-7 stable lines expressing
pLenti6/v5 (Empty), pLenti6/v5 CNNM3 WT (CNNM3 WT), and pLenti6/v5 CNNM3 D426A (CNNM3 D426A) was performed using CyQUANT DNA dye after
culturing the cells with standard growthmedium (left panel), magnesium-freemedium supplementedwith 1mMMgCl2 (center panel), or without supplemen-
tation (right panel). Values aremean S.D. ***, p0.0001 by two-way ANOVA followed bymultiple comparison test. B and C, DB-7 stables lines were tested
for their potential to form colonies in soft agar by quantifying the number of colonies (B) and the percentage of small (50 to500 pixels), medium (500 to
1000 pixels), and large (1000 pixels) colonies (C), normalized to total colony number per group. Values aremean S.E. *, p 0.0039; **, p0.0001;N.S.,
not significant by one-way ANOVA followed by multiple comparison test. D, representative pictures of soft agar assays from DB-7 stable lines at 10
magnification.
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PRL-2 expression was shown previously to correlate with
cancer progression (3, 35), and PRLs were demonstrated
recently to interact with CNNMs to promote oncogenesis by
regulating intracellular levels of magnesium (5, 9). Here we
characterized more precisely the interaction using various
pointmutants that lead to themodeling of the interaction using
previously published structures of the Bateman module of
CNNM2 and PRL-1 (36, 37). The modeled structure of the
interaction in Fig. 1F shows that amino acid 426 of CNNM3
binds in the catalytic site of PRL-2, which interferes with poten-
tial substrate binding. These results confirm our previously
proposed model that CNNM3 is not a substrate of PRL-2 (5).
The PRL phosphatases are known to be poorly active, using in
vitro enzymatic assays with synthetic substrates, and the few
putative substrates remain to be confirmed (5–7). Thus, this
can explain the difficulty for identifying PRL-2 physiological
substrates if the major role of this PTP resides upon binding
with CNNM3 to regulate magnesium transport. On the other
hand, this does not exclude potential CNNM3 or PRL-2 mutu-
ally exclusive roles.
The structural modeling also suggests that using an inhibitor
targeting the catalytic pocket of PRLs would inhibit its interac-
tion with CNNMs. Thienopyridone has been shown to selec-
tively inhibit PRL activity compare with other PTPs and also
had an antiproliferative effect in cancer cells (32). Although this
effect on cell growth was associated with the loss of PRL activ-
ity, we speculated that it could potentially be caused by the
disruption of the PRLCNNM complex. Here we showed that
indeed this molecule blocked the in vitro interaction of PRL-2
with CNNM3 and to also reduced MCF-7 breast cancer cell
proliferation, thus corroborating our hypothesis. This experi-
ment creates an opportunity to further investigate the effect of
PRL inhibitors that have been developed recently (33) on PRL-
CNNM complex formation. Moreover, it is a proof of concept
to further explore the possibility of blocking this interaction for
clinical purposes in cancer therapy.
We previously uncovered that the loop region of the second
CBS of the Batemanmodule of CNNMs and PRL phosphatases
appear at the same stage during evolution (5). Interestingly,
here we showed that specific amino acids of this region are
almost fully conserved, andwhenwemutated them inCNNM3,
they lost the interaction with PRL-2. Moreover, a point muta-
tion of the conserved aspartic acid in this loop is sufficient to
block complex formation, resulting in reduced tumor growth.
The CNNM3D426Amutant has a dominant negative effect on
cancer cell proliferation in magnesium-deprived medium.
Consistent with this, a previous observation showed that low
magnesium promotes the PRL-2/CNNM3 association (5).
Thus, blocking this associationwill severely hinder the ability to
proliferate when magnesium is less available. Because cancer
cells have to adapt to survive the harsh tumor microenviron-
ment (38), this could explain the mechanistic basis for the high
expression levels of PRLs observed in various cancers.
Although electrophysiological studies have been previously
performed on CNNM2, the mechanism of action of this sub-
family of magnesium transporter remains poorly characterized
because published results remain ambiguous. Stuiver et al. (18)
showed than an increase in extracellular Mg2 blocked
CNNM2 influx. In contrast, Quamme (14) observed the oppo-
site, where high extracellularMg2 promotes CNNM2 current.
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FIGURE 4. Disruption of the PRL-2CNNM3 complex formation decreases tumor growth in a xenograft mouse model. A, mice (NU/J, 6 weeks old) were
injected in themammary fat pad with DB-7mammary cancer cells stably expressing CNNM3WT or the CNNM3D426Amutant and a luciferase reporter gene.
B, after injection, tumor sizesweremonitoredby luciferasebioluminescence through total flux (photons/second) *,p0.0447; **,p0.0043; ***,p0.0001.
C, caliper measurements were takenwhen the tumors were visible. Values aremean S.D. *, p 0.0122; **, p 0.0057; ***, p0.0001 by two-way ANOVA
followed bymultiple comparison test.D, tumorwere dissected out at the end point andweighed. Values aremean S.D. *, p 0.0104; **, p 0.0046; ***, p
0.0001 by one-way ANOVA followed by multiple comparison test. E, representative picture from all groups in the first 10 days (n 8/group).
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Todate, CNNM2 is the onlymember of theCNNMfamily to be
tested by patch clamping. To clarify themechanism of action of
CNNM3, we examined its propensity to alter voltage gating.
Our novel electrophysiological analysis indicates that the
expression of CNNM3 increased the cellular current under
hyperpolarization conditions, as similarly observed for
CNNM2 (18). Moreover, because the T568I mutation in the
second CBS domain of CNNM2 has been described in patients
with dominant hypomagnesemia to result in a smaller Mg2-
sensitive current when overexpressed in HEK293 cells (18) and
because the T568Imutation inCNNM2 is known to disrupt the
binding with Mg2/ATP (9, 16, 39), we also tested the corre-
sponding (T436I) threonine in CNNM3. Here we observed a
decrease in binding of PRL-2 when this corresponding threo-
nine was mutated in CNNM3, suggesting a possible role for
PRL in this CNNM-associated genetic disease. Concomitantly,
we also did not detect any changes in cell current in the pres-
ence of CNNM3 D426A, strongly indicating that the contribu-
tion of PRL-2 binding in the complex is essential for CNNM3-
induced cellular current that will lead to increase tumor
growth. In support of this view, it is well established that cancer
cells proliferate in a state of hyperpolarized membrane (40),
which correlates with our findings with CNNM3 at 50 mV.
Overall, those findings support the view that the mechanism of
action of CNNMs requires the binding of PRLs to trigger a rise
in intracellular magnesium levels, as proposed previously (5, 9).
Here the overexpression of both the CNNM3 wild type or
binding mutants was found at the plasma membrane indepen-
dent of PRL-2 expression, suggesting that, although its binding
affects magnesium transport, its presence does not influence
CNNM3 localization. Also, CBS-PRL complex modeling indi-
cates (Fig. 1F) that a single point mutation of the aspartate does
not severely disturb the folding of CNNM3 because themutant
was properly localized at the membrane. Similarly, the T568I
point mutation in the second CBS of CNNM2 was also cor-
rectly directed to the plasma membrane (18). On the other
hand, in chloride channels from theCLC family, the presence of
structurally functional CBS domains has been shown to influ-
ence, either directly or indirectly, their subcellular localization
(41). Still, using confocal microscopy, Hirata et al. (42) showed
that deletion of the Bateman domain in CNNM2 and CNNM4
similarly did not affect their presence at the plasmamembrane.
The PRL phosphatases share high sequence identity with
each other, and the CBS domains of CNNMs are also highly
conserved (5, 43). Nevertheless, different PRL-CNNM com-
plexes were reported to have different ways of regulating mag-
nesium transport but similar consequential effects on intracel-
lular magnesium levels. Our group showed previously that the
PRL-2CNNM3 complex promotes breast cancer progression
by regulating magnesium influx (5). On the other hand, Funato
et al. (9) suggested that PRL-3 binding to CNNM4 blocked its
efflux activity to promote colon cancer development. Despite
these differences, the consequences of both proposed models
lead to an increased intracellular magnesium concentration. In
addition, CNNM2 activity was suggested previously to regulate
the TRPM7 magnesium channel (19) that is associated with
breast cancer growth and metastasis (44, 45), which may also
provide a thirdmodel ofmagnesium regulation in cancer by the
PRL-CNNM complex. Further molecular, structural, and bio-
logical studies are needed to decipher the exact roles of each
PRL-CNNM complex. Still, not only is this mechanism novel,
but the PRL-dependent magnesium level modulation could
also explain the observations relating to the array of signaling
pathway activation reported in the past decade in response to
PRL overexpression (1, 3, 6). For instance, it was observed
recently that overexpression of PRL-3 promotes mechanistic
target of rapamycin phosphorylation (46) and that this enzyme
is critical for the control of mRNA translation (47). Because
both protein phosphorylation and mRNA translation are
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FIGURE 5. Thienopyridone blocks the interaction between PRL-2 and the
Batemanmodule of CNNM3 to reduce proliferation. A, in vitro interaction
of PRL-2 with the CBS tandem domain of CNNM3. His-PRL-2, GST-2xCBS and
GST alone were produced in bacteria. GST pulldown was performed with
equimolar amounts of both proteins with various concentrations of thien-
opyridone. The control (CTRL) represents the binding between 2xCBS and
PRL-2 without inhibitor. B, real-time analysis of the effect of thienopyridone
on MCF-7 cell using the xCELLigence system. The dotted box represents the
linear phase of cell proliferation.DMSO, dimethyl sulfoxide;NT, not treated.C,
the slope (1/h), representing the cell ability to proliferate was calculated
based on the cell index values in the linear phase of the plot (dotted box)
described in B. Each drug condition was done in triplicate, and the results are
represented as mean  S.D. *, p  0.0231 by one-way ANOVA followed by
multiple comparison test. Dimethyl sulfoxide was used as a vehicle control.
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strongly dependent on magnesium availability (48–50), it is
reasonable to speculate that the action of PRLs is to provide
enough magnesium for those processes via complex formation
with the CNNMs, and this could explain the increase in mech-
anistic target of rapamycin activity observed in this study.
Together, our data unveiled the importance of the highly
conserved amino acid loop present in CNNMs toward modu-
lating their binding to PRLs. Furthermore, we showed that this
binding is crucial to the oncogenic activity of PRLs in various
types of tumors. We trust that, by inhibiting the formation of
PRL-CNNMcomplexes, we are opening new avenues in cancer
therapy suitable to a large array of human cancer types where
PRLs are overexpressed.
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